HDACI and DAC induce specific epigenetic profile in DLBCL

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid neoplasm in the world representing 30-40% of all lymphomas. Standard immunochemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) ensures cure in 60 to 65% of patients, while the rest progress or relapse. While advances have been made in the treatment of DLBCL, especially with the addition of rituximab, it is now apparent that there may be significant differences in prognosis that are related to the cell of origin, and that this disease is heterogeneous and novel treatment options are needed. It has been hypothesized that the combination of HDACI and hypomethylating agents might be a new approach to the treatment of relapsed or refractory DLBCL. This combination is thought to disrupt the

ORGANISM(S): Homo sapiens

SUBMITTER: Matko Kalac 

PROVIDER: E-GEOD-27226 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress